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0929-6646/Copyright ª 2015, ElsevierBackground/purpose: Understanding the mechanisms of protecting the kidneys from injury is
of great importance because there are no effective therapies that promote repair and the kid-
neys frequently do not repair adequately. Evidence has shown that erythropoietin (EPO) has a
vital renoprotective role, independent of its erythropoietic effect. However, whether EPO can
contribute to kidney repair after injury and the potential mechanisms are not fully under-
stood.
Methods: To investigate the renoprotective mechanism of EPO, a kidney ischemia/reperfu-
sion injury (IRI) model was induced in adult male SpragueeDawley rats. The rats were
subsequently randomly treated with EPO or a vehicle 6 hours after the kidney IRI. The
rats were sacrificed on Day 3, Day 5, and Day 7 post kidney IRI. Renal function and
histological alterations were examined. Renal interstitial macrophage infiltration, cell pro-
liferation, apoptosis, and angiogenesis were evaluated by immunostaining. Furthermore,
the effects of EPO on the Wnt/b-catenin pathway and IRI-related micro-RNAs were investi-
gated.
Results: The administration of EPO significantly improved renal function and reduced
tubular injury. Furthermore, EPO treatment significantly prevented tubular cell apoptosis
and promoted cell proliferation after IRI. Erythropoietin significantly suppressed macro-
phage infiltration, compared to the vehicle. In addition, treatment with EPO markedly pre-
vented the loss of microvasculature. We have also demonstrated that, compared to the
vehicle, EPO administration enhanced the expression of Wnt7b and b-catenin, and downre-
gulated miR-21, -214, -210, and -199a.have no conflicts of interest relevant to this article.
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Erythropoietin attenuates kidney injury 431Conclusion: Erythropoietin protects the kidneys against IRI by attenuating injury of the renal
microvasculature and tubule epithelial cells, by promoting Wnt/b-catenin pathway activa-
tion, and by regulating miRNA expression.
Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Renal ischemia/reperfusion injury (IRI) is a common cause
of acute kidney injury (AKI).1,2 It results from a sudden
transient drop in total or regional blood flow to the kid-
neys.3 Despite advances in preventative strategies and
support measures, this disease is associated with significant
morbidity and mortality.2 Many treatment strategies have
been proposed to improve IRI, but few are effective.3
Erythropoietin (EPO) is a hematopoietic hormone pro-
duced primarily by the adult kidneys.4 It is a multifunctional
cytokine involved in a variety of processes in the kidneys,
liver, and brain that are independent of erythropoiesis. Evi-
dence has demonstrated that EPO has cytoprotective ef-
fects, which mediate antioxidative stress, antiapoptosis/
necrosis, and anti-inflammatory responses,5,6 and immuno-
modulation of autoimmune diseases.7 Erythropoietin may be
an efficient renoprotective agent against renal dysfunction
and injury.However, theprecisemechanismsofEPO involved
in kidney IRI have not yet been fully elucidated.
The term “acute tubular necrosis” is used to designate
AKI resulting from characteristic pathologic damage to the
tubules. The improvement of renal function after kidney IRI
primarily depends on the repair and regeneration of injured
tubular epithelial cells.8,9 In particular, IRI causes sterile
inflammation, which increases the production of inflam-
matory cytokines and infiltration of neutrophils and mac-
rophages.10 Peritubular capillary (PTC) loss is also positively
associated with tubular damage in the kidneys in ischemic
AKI and in the clinical biopsy.11,12 Our previous studies also
suggested that PTC loss because of ischemia is directly
correlated with impaired renal function and the develop-
ment of renal fibrosis.13,14 Promoting the repair and
regeneration of injured kidney vasculature successfully
reverses these pathological changes.14,15
Wnt signaling was originally identified as involved in the
developmental fate decision and neoplasia. The canonical
Wnt pathway can drive cell proliferation and maintain the
dedifferentiated state of cells. It also has a critical role in
kidney repair and regeneration after IRI.16 Reparative
macrophages may secrete Wnt ligands, which interact with
Wnt-expressing receptors on the epithelial cell surface to
repair the injured kidney.13 Micro-RNAs (miRNAs) are
endogenous noncoding RNAs that posttranscriptionally
regulate gene expression. Research studies have shown that
miRNAs are involved in various different biological pro-
cesses such as hypoxia, differentiation, inflammation, cell
proliferation, cell death, and fibrosis in kidney disease,17,18
and in kidney IRI.19 Whether EPO can regulate miRNAs in
kidney IRI is unknown.
In this study, we aimed to reveal the multifaceted
renoprotective roles of EPO in kidney IRI from variousrespects such as tubular cell apoptosis; macrophage infil-
tration; the loss of microvasculature; and the expression of
Wnts, b-catenins, and IRI-related miRNAs such as miR-21,
-199a, -210, and -214. Such efforts may provide better
understanding of the renal-friendly benefits of EPO.
Materials and methods
Animals
Male SpragueeDawley (SD) rats weighing 200e250 g were
purchased from the Second Affiliated Hospital of Harbin
Medical University Laboratories (Harbin, China). All exper-
iments were conducted in accordance with the National
Institutes of Health Guidelines for the Care and Use of
Laboratory Animals. All rats were maintained in filter top
cages and received sterilized food and acidified water.
Experimental protocols were approved by the animal
committee of Harbin Medical University (Harbin, China).
Animal model
Male SD rats (200e250 g) were subjected to kidney IRI by
methods described previously.13,14 The warm ischemic time
was 45 minutes (i.e., the unilateral model) or 40 minutes
(i.e., the bilateral model). All male SD rats were randomly
divided into three groups: the sham group, the EPO group,
and the vehicle group. Six hours after inducing unilateral
IRI, the unilateral model rats intraperitoneally received
2000 IU/kg EPO (EPO group; n Z 24; rhEPO; Roche, Man-
nheim, Germany) or received the vehicle (vehicle group;
n Z 24). The sham-operated rats, which underwent the
same surgical procedure but without the placement of the
vascular clamp, served as controls (i.e., sham group). The
rats were sacrificed on Day 3, Day 5, and Day 7 after the
operation (n Z 8 rats per time point).
Six hours after the IRI, the rats with bilateral IRI also
received rhEPO (Roche; i.e., EPO group) or the vehicle
(i.e., vehicle group). Plasma samples were drawn from the
tail vein on Day 1, Day 3, and Day 7 after injury to analyze
the creatinine level using previously described
methods.13,14 The bilateral model rats were sacrificed on
Day 7 (n Z 8 rats per group).
Tissue preparation, immunostaining, imaging, and
quantification of injury and repair
Rats were perfused with ice cold normal saline, and then
preserved in opti-mumcutting temperature compound
(OCT) (80C) and paraffin by using previously described
methods.13,14 The paraffin sections (3 mm) were processed
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cence labeling was performed on 4 mm cryosections. Pri-
mary antibodies against the following proteins were used:
rabbit anti-rat CD68 (1:200, Abcam; Hong Kong, China);
rabbit anti-rat Ki67 (1:200, clone SP6; Thermo Scientific,
Fremont, CA, USA); mouse anti-rat RECA-1 (1:20; Abcam,
Hong Kong, China), and rabbit anti-rat b-catenin (1:200;
Abcam, Hong Kong, China). The secondary antibodies were
Alexa Fluor 488-conjugated goat antirabbit; Alexa Fluor
594-conjugated donkey antimouse and Alexa Fluor 594-
conjugated goat antirabbit (1:200; Jackson ImmunoR-
esearch Laboratories, West Grove, PA, USA).
The HE-stained paraffin sections used a blinded scoring
method, as reported by our previous research.14 For each
square, the presence of tubule injury (e.g., tubule flat-
tening, necrosis, apoptosis, or the presence of casts) was
a positive score. The final score was presented as the
percentage of positive squares. Macrophages were iden-
tified as positive for CD68 if > 75% of the cell area sur-
rounding the nucleus exhibited Alexa Fluor 488
fluorescence. Specific cells were counted in 10 random
cortical interstitial fields per rat. Apoptotic cells were
detected by a terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) apoptosis assay kit (Roche,
Indianapolis, IN, USA), as previously described.14 Nuclei
were stained using 4,6-diamidino-2-phenylindole. Peri-
tubular capillary (PTC) loss was determined by assessing
anti-RECA-1. In brief, images were captured by digital
imaging (200 magnification) sequentially over the entire
sagittal section, which incorporated the cortex and outerTable 1 Primers (mouse) used in the experiment.
The studied gene Sequen
Wnt7b F CCTTCA
R TGCCT
GAPDH F CGCAT
R GAGGG
rno-miR-21-5p RT GTCGT
F GCGGC
R ATCCAG
rno-miR-192-5p RT GTCGT
F GCGGC
R ATCCAG
rno-miR-24-3p RT GTCGT
F GCGGC
R ATCCAG
rno-miR-214-3p RT GTCGT
F GCGGC
R ATCCAG
rno-miR-210-3p RT GTCGT
F GCGGC
R ATCCAG
rno-miR-199a-3p RT GTCGT
F GCGGC
R ATCCAG
U6 RT CGCTT
F GCTTC
R CGCTT
F Z forward; R Z reverse; RT Z reverse transcription.medulla (10e20 images). Each image was divided into 192
squares by a grid. A square without a PTC was considered
positive for loss. Images of b-catenin staining were
captured in 10 random medullar fields per rat, and the
mean area of positive staining was quantified. Images
were obtained by Nikon microscopy (Nikon, Tokyo, Japan)
and processed by NIS-Elements software.
Real-time polymerase chain reaction
Real-time polymerase chain reaction (PCR) was used for
the quantitative detection of messenger RNA (mRNA) and
micro-RNA expression. TRIzol reagent (Invitrogen,
Shanghai, China) was used to extract RNA from cry-
opreserved renal tissue (80C). The RNA was reverse
transcribed into cDNA by using a high-capacity cDNA
reverse transcription kit (Applied Biosystems, Foster City,
CA, USA). Table 1 shows the valid sequences of the
primers. For real-time PCR, 2SYBR Green PCR Master Mix
(Applied Biosystems, Warrington, United Kingdom) was
used in accordance with the manufacturer’s instructions
with the Bio-Rad CFX96 real-time PCR detection system
(Bio-Rad, Singapore, Singapore). After a brief heating of
10 minutes at 95C, amplification was performed, as fol-
lows: 95C for 15 seconds, 60C for 1 minute, and 40 cy-
cles. Cycle threshold values of the mRNA were normalized
to those of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), and the cycle threshold values of the miRNA
were normalized to those of U6. Fold differences in gene
expression were determined using the 2eDDCT method, andce of oligonucleotides
CATACGCCATCACC
GGTTGTAGTAGCCTTG
CTTCTTGTGCAGTG
TGCAGCGAACTTTATT
ATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCAACA
GGTAGCTTATCAGACTG
TGCAGGGTCCGAGG
ATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGGCTGT
GGCTGACCTATGAATTG
TGCAGGGTCCGAGG
ATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTGTTC
GGTGGCTCAGTTCAGCAG
TGCAGGGTCCGAGG
ATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTGCCT
GGACAGCAGGCACAGAC
TGCAGGGTCCGAGG
ATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCAGCC
GGCTGTGCGTGTGACAG
TGCAGGGTCCGAGG
ATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTAACCA
GGACAGTAGTCTGCAC
TGCAGGGTCCGAGG
CACGAATTTGCGTGTCAT
GGCAGCACATATACTAAAAT
CACGAATTTGCGTGTCAT
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on Day 3.
Statistical analysis
All values are presented as the mean  the standard de-
viation. One-way analysis of variance (ANOVA) with the
SteeleDwass test was employed to analyze multiple com-
parisons. A value of p < 0.05 was considered significant in
all statistical tests. All tests were conducted using SPSS 17.0
software (SPSS Inc., Chicago, IL, USA).Results
The administration of EPO improves renal function
and attenuates pathological alteration after kidney
IRI
Serum creatinine was assessed in the sham surgery rats on
Day 0, and then on Day 1, Day 3, and Day 7 after bilateral
kidney IRI. Bilateral IRI resulted in a level that was seven
times higher (3.91  0.31 mg/dL), compared to the pre-
operative level (Day 0, 0.52  0.14 mg/dL). By contrast,
the level of serum creatinine after EPO treatment was
significantly decreased on Day 1, Day 3, and Day 7 after
kidney IRI (Fig. 1A). After the IRI, the renal tubules also
showed remarkable injury such as tubular swelling and
deformation, expansion, inflammatory cell infiltration,
tubular epithelial cell degeneration and necrosis, and
accumulation of necrotic material within the lumen.
Treatment with EPO significantly attenuated these patho-
logical changes (Fig. 1B). These results are expressed
graphically in Fig. 1C.Figure 1 Erythropoietin (EPO) treatment post kidney ischemia/
tubule injury. (A) Serum creatinine levels on Day 0, Day 1, Day 3, an
with saline or EPO 6 hours after reperfusion. (B) Representative ligh
of the renal outer medulla from every group (magnification, 200
group. #Indicates significance at p < 0.01, versus the sham group.
**Indicates significance at p < 0.01, versus the vehicle group.Therapy by EPO prevents cell apoptosis, promotes
cell proliferation, and attenuates macrophage
infiltration and PTC loss after kidney IRI
To further study the mechanism of reduced renal injury by
EPO, we analyzed kidney sections for cellular apoptosis and
proliferation. The number of TUNELþ apoptotic cells
increased rapidly in a short time, and gradually decreased
with reperfusion time. Treatment with EPO significantly
reduced the number of apoptotic cells, as Fig. 2A shows. In
addition, the pan cell cycle marker Ki67 was used to label
the cell cycle of the kidney cells. The administration of EPO
significantly enhanced proliferation, compared to the pro-
liferation in the kidneys of untreated rats on Day 5 and Day
7 after IRI (Fig. 2B).
A significant increase in macrophages was observed in the
IRI rats, compared to the number ofmacrophages in the sham
surgery rats. We also observed that EPO could suppress the
number of CD68þmacrophages, especially on the 5th day and
7th day after IRI (Fig. 2C). To analyze PTC regeneration, we
used RECA-1 as a marker of endothelial cells to evaluate PTC
loss. Peritubular capillary loss increased in kidney tissues
with IRI, but significantly improved after EPO treatment on
Day 3, Day 5, and Day 7 (Fig. 2D).
Erythropoietin participates in renal protection
through activating the Wnt/b-catenin pathway post
kidney IRI
We observed that Wnt7b mRNA content increased rapidly
within a short time and reached its peak on the 3rd day after
AKI. The content thereafter gradually declined. Based on
quantitative analysis, Wnt7b expression in the EPO treat-
ment group was significantly higher than that of the vehiclereperfusion injury (IRI) improves renal function and reduces
d Day 7 after bilateral IRI, followed by intraperitoneal injection
t microscopy images of hematoxylin-eosin (HE)-stained sections
). (C) The graph shows the renal tubular injury score in every
*Indicates significance at p < 0.05, versus the vehicle group.
Figure 2 The administration of erythropoietin (EPO) regulates cell proliferation and apoptosis, and suppresses macrophage infil-
tration and peripheral capillaries loss induced by kidney ischemia/reperfusion injury (IRI). (A) Representative images of transferase
dUTPnick end labeling (TUNEL) staining (brown) of the ischemia/reperfusion-injured kidney that received the vehicle or EPOonDay 3,
Day5, andDay7after surgery. Thegraph shows thenumber of apoptotic cells in themiceafter theadministrationof the vehicle or EPO.
(B) Representative Ki67 immunofluorescence images of ischemia/reperfusion-injured kidneys that received the vehicle or EPOat each
time point. The graph shows the number of proliferative cells for mice after vehicle or EPO. (C) Representative CD68 immunofluo-
rescence images of ischemia/reperfusion-injured kidneys that received the vehicle or EPO at each time point. The graph shows the
number of macrophages in the mice after the administration of the vehicle or EPO. (D) Representative images of rat RECA-1-labeled
peritubular capillaries of the outer medulla on Day 7 post ischemia/reperfusion injury of kidneys that received the vehicle or EPO at
each time point. The graph shows peritubular capillary loss in themice after the administration of the vehicle or EPO. (Magnification,
200; #p < 0.01, vs. the sham group; *p < 0.05 and **p < 0.01, vs. the vehicle group). DAPIZ 4,6-diamidino-2-phenylindole.
434 X. Chen et al.group on the 3rd day and 5th day after IRI (Fig. 3A). The
expression of b-catenin, a key downstream signaling protein
of the Wnt/b-catenin pathway, was significantly increased
and peaked on the 5th day (Fig. 3B and 3C). After EPO
treatment, b-catenin expression was significantly enhanced,
especially on the 5th day after the kidney IRI (Fig. 3B and 3C).Erythropoietin affects the expression of IRI-related
miRNAs
Numerous studies have indicated miRNAs have an impor-
tant role in regulating hypoxia, cell survival, apoptosis,inflammation, and other processes. Therefore, we
investigated whether EPO administration could regulate
miRNAs. In our study, we specifically examined
cell apoptosis, proliferation, and fibrosis-related miRNAs
such as miRNA21, miRNA214, and miRNA192. We observed
that miR-21 and -214 were upregulated after the IRI.
However, their expression was reduced after EPO treat-
ment (Fig. 4A and 4B). Erythropoietin had no effect on the
expression of miR-192 (Fig. 4C). We also detected
hypoxia-related miR-210 and -199a. We found that
increased expression of these two miRNAs after the IRI
was markedly suppressed by EPO treatment (Fig. 4D
and 4E).
Figure 3 Erythropoietin (EPO) enhances the activation of the Wnt/b-catenin signaling pathway after ischemia/reperfusion injury
(IRI) of the kidneys. (A) The graph shows the expression of a critical Wnt, Wnt7b, on Day 3, Day 5, and Day 7 post kidney IRI after
vehicle or EPO administration by real-time polymerase chain reaction [PCR; normalized to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH)]. (B) Representative b-catenin immunofluorescence images of the ischemia/reperfusion-injured kidneys that
received the vehicle or EPO at each time point. (C) The graph indicates b-cateninepositive areas for mice after the administration
of vehicle or EPO (magnification 200; #p < 0.01, vs. the sham group; *p < 0.05 and **p < 0.01, vs. the vehicle group).
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Acute kidney injury induced by IRI is a common clinical
problem and has a mortality rate of 25e70% because of
limited treatment.20 Therefore, it is very important to seek
new treatment strategies. Erythropoietin is a glycoprotein
that has a critical hormonal role in regulating erythrocyte
production, and it can protect a wide variety of tissues
from diverse injuries in addition to its role in eryth-
ropoiesis.4,21e23 In the present study, we demonstrated that
EPO administration can significantly improve renalFigure 4 EPO regulates the expression of IRI-related miRNAs. (Ae
and -199a on Day 3, Day 5, and Day 7, after kidney ischemia/reper
time PCR (normalized to U6) (#p < 0.05, ##p < 0.01, and ###p < 0.0
vs. the vehicle group).function, prevent tubular cell apoptosis, and promote cell
proliferation after IRI. Furthermore, EPO treatment sup-
pressed macrophage infiltration and prevented loss of the
microvasculature. Furthermore, EPO clearly enhanced the
expression of Wnt7b and b-catenin and regulated the
expression of IRI-related miRNAs.
Erythropoietin has validated anti-inflammatory, -oxidant,
and -apoptotic effects when it is used prior to
ischemia.5,24e27 However, most studies have focused on EPO
preconditioning in kidney IRI. In this experiment, we aimed
to observe whether, with the exception of its prophylacticE) The graph shows the expression of miR-21, -214, -192, -210,
fusion injury (IRI) after vehicle or erythropoietin (EPO) by real-
01, vs. the sham group; *p < 0.05, **p < 0.01, and ***p < 0.001,
436 X. Chen et al.role, EPO treatment at an early stage could contribute to
kidney repair and regeneration after injury. After treatment,
the serum creatinine level decreased significantly and the
renal function improved. In addition, the renal tubular
damage index and cell infiltration of renal interstitial
inflammation were reduced, which morphologically showed
great improvement of the kidney injury. To our knowledge,
EPO is prophylactic and effective is a new finding, even
though it was administered during perfusion periods.
Cell necrosis and apoptosis were generated with
decreased glomerular filtration rate.28 In the present study,
we observed apoptosis of renal cells in IRI model and found
apoptosiswas enhancedat the early stageof IRI, especially in
the epithelia. The administration of EPO markedly inhibited
apoptosis. This antiapoptotic effect may involve multiple
mechanisms such as EPO on its receptor protecting the
tubular cells,9,29 EPO inducing the expression of heme oxy-
genase 1 (HO-1) against oxidative stress,30 and EPO blocking
the passing down of apoptotic signaling pathways.31 In
addition, the replacement and regeneration of renal tubular
epithelial cells may be key in the recovery from kidney IRI.32
We found that the proliferation of tubular epithelial cells
decreased with the extension of the reperfusion time. After
EPO treatment, epithelial cell proliferation was enhanced
during the late stage after IRI, which may result from an EPO
post-treatment effect or long-term restoration.
Emerging evidence indicates that the integrity of the PTC
network is a key determinant of the preservation of renal
function.33 Our study showed that the loss of PTCs increased
in kidney tissue after ischemia/reperfusion, but this loss was
significantly ameliorated after EPO treatment, especially
after 3 days. Certain past findings have also proven that EPO
has a direct biological effect on endothelial cells34 and
endothelial progenitor cells,35 and hence contribute to the
vascular repair process and vascularization.36
Vascular endothelial damage and dysfunction also lead
to inflammatory cell infiltration.2 In our study, we observed
significant increases in macrophages. In general, macro-
phages have an important role in mediating injury and
repair after IRI, which depends on macrophage phenotypes.
During the early stages of IRI, macrophages have a proin-
flammatory role in mediating injury; during the late phase,
they transform themselves into the anti-inflammatory
phenotype to repair injury.37,38 In this study, the increase
in CD68þ macrophages could be mitigated by EPO treat-
ment after IRI.
Our previous study and other investigations have shown
that the Wnt pathway is activated and has an indispensable
role during repair and regeneration in animal models of
acute ischemic injury.13,16 In this experiment, we also
observed the Wnt/b-catenin signal pathway is sequentially
activated after kidney IRI. Wnt7b, a Wnt pathway ligand, is
a critical tissue ligand in the preparation of kidney damage.
This ligand’s mRNA expression increased rapidly within a
short time and reached its peak on Day 3 after the acute
kidney IRI. This finding indicated the process of reparation
and regeneration by activation of the Wnt/b-catenin
pathway.13 To our astonishment, EPO further enhanced the
repair signals of Wnt7b and b-catenin, compared to
signaling in the IRI group. Erythropoietin inhibited the
infiltration of macrophages, which is the major source of
Wnt7b, although it did not alter the increase in expression.This may be because EPO treatment promotes the prolif-
eration of tubular epithelial cells and endothelial cells
(which are also capable of secreting Wnt7b) or because it
promotes the phenotype switch of macrophages from
proinflammation to proreparation. Further study needs to
be investigated in the future.
Numerous hallmarks of kidney disease such as hypoxia,
apoptosis, proliferation, inflammation, epithelial-
mesenchymal transition, and fibrosis are regulated by
miRNAs.17e19 Research studies have confirmed that miR-21
and -214 have a role in regulating cellular proliferation,
preventing apoptosis, and promoting renal fibrosis by
regulating the transforming growth factor-b signaling
pathway.17,18,39e41 Our findings indicated that miR-21 and
-214 were upregulated, whereas miR-192 was down-
regulated after the IRI. These findings were in line with the
findings of a previous study.19 In addition, EPO administra-
tion reduced the expression of miR-21 and -214, but
inconspicuously influenced miR-192 expression. This finding
may be because the potential roles of miR-192 in IRI and
fibrosis remain controversial.18 Furthermore, the mecha-
nism of the regulation of miR-192 expression remains un-
clear. We also detected miR-210 and -199a expression,
which is associated with hypoxia and angiogenesis.42,43 In
particular, we discovered that the expression of these two
miRNAs increased after IRI. Erythropoietin also suppressed
the overexpression of the two miRNAs. We did not find
sufficient evidence of EPO directly regulating these miR-
NAs, although these miRNAs may represent new biomarkers
of renal injury, as previously reported.19
In summary, our study elucidated that EPO improved
renal function, reduced apoptosis, and decreased tubular
injury after kidney IRI. We further confirmed that EPO
promoted the regeneration of kidney tubules, and pre-
vented PTC loss. The functional and histological benefits of
EPO on the kidneys after IRI were accompanied by activa-
tion of Wnt7b/b-catenin and downregulation of miR-21,
-214, -210, and -199a. Whether these findings are respon-
sible for the renoprotective effect of EPO needs further
studies. Our results strongly suggest that EPO could be a
promising therapeutic strategy against the pathological
development of AKI caused by IRI.
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